TheraCell, an allograft solution company, has been acquired by Isto Biologics, provider of surgical-based orthobiologic regeneration technologies and cell-based therapies. The acquisition will bolster Isto's focus on offering solutions for surgical and clinical care procedures within spine, orthopedics and sports medicine.
The acquisition will expand Isto Biologics' growing portfolio of orthopedic grafts and introduce TheraCell's proprietary and patented TheraFuze DBF® technology (shown above) that will become part of Isto Biologics' Influx™ line.
Bradley Patt, PhD, TheraCell's Co-Founder and CEO said, "We are pleased that Isto, a leader in allogeneic spine solutions, has recognized the value and importance of what we have developed and are excited about how their patient-centric, outcomes-focused commercial and clinical teams will rapidly accelerate the surgical adoption of the products and technology that we are so passionate about."
"We are thrilled to add TheraCell's unmatched technology to our market leading biologics portfolio," said Don Brown, CEO of Isto Biologics. "TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade including their award winning TheraFuze DBF® Fiber Anchor™ and TheraFuze DBF® Fiber Bag™."
Source: TheraCell and Isto Biologics